Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01835535




Registration number
NCT01835535
Ethics application status
Date submitted
17/04/2013
Date registered
19/04/2013
Date last updated
26/03/2014

Titles & IDs
Public title
Continued Safety and Performance of the TIVUS System
Scientific title
Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Renal Denervation in Patients With Resistant Hypertension
Secondary ID [1] 0 0
CLN02-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertension, Resistant to Conventional Therapy 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Severe Resistant HTN - Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in office Systolic Blood Pressure (SBP) from baseline to 6-month
Timepoint [1] 0 0
6 month
Secondary outcome [1] 0 0
Procedural complications
Timepoint [1] 0 0
30 day
Secondary outcome [2] 0 0
Major Adverse Events (MAE)
Timepoint [2] 0 0
1 year
Secondary outcome [3] 0 0
Preservation of renal function
Timepoint [3] 0 0
1 year
Secondary outcome [4] 0 0
Cardiovascular complications
Timepoint [4] 0 0
1 year
Secondary outcome [5] 0 0
Blood pressure reduction
Timepoint [5] 0 0
1 year

Eligibility
Key inclusion criteria
* Patient is = 18 and = 80 years of age
* For Cohort A: Documented office systolic blood pressure > 160 mmHg (> 150 mmHg for diabetic patients); For Cohort B: Documented office systolic blood pressure > 140 mmHg (> 130 mmHg for diabetic patients); For Cohort C: Documented office systolic blood pressure > 150 mmHg (> 140 mmHg for diabetic patients)
* Documented 24 hour systolic ABPM > 135 mmHg
* Adherence to a stable drug regimen
* For patients in Cohort C only: Documented renal denervation procedure with any RF technology 12 months or more prior to screening
* Suitable renal artery anatomy
* Male or non-pregnant / non-lactating female
* Patient understands the nature of the procedure and provides written informed consent
* Patient is willing and able to comply with the specified study requirements and follow-up evaluations
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* eGFR < 45mL/min/1.73m2
* Documented primary pulmonary hypertension
* Patient experienced >1 episode of orthostatic hypotension coupled with syncope
* Documented indicator of a secondary renal hypertension
* History of myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months
* Planned major surgery or cardiovascular intervention in the next 6 months
* Surgery or cardiovascular intervention in the previous 3 months
* Hemodynamically significant valvular heart disease
* Severe debilitating lung disease
* Patient on anticoagulant therapy that cannot be temporarily withheld for performing catheterization
* Patient has a single functioning kidney
* Documented thrombocytopenia, clotting disorders or aortic aneurysms
* Moribund patient, or patient with comorbidities limiting life expectancy to less than one year
* Contraindication to recommended study medications or intravascular contrast material that cannot be adequately controlled with pre-medication
* Concurrent enrollment in another trial
* Main renal arteries < 4 mm in lumen diameter or < 20 mm in length
* Aorto-renal angle that prevents a safe cannulation of the renal artery
* Severe common femoral artery, common and/or external iliac artery, renal, iliac or aortic calcification or tortuosity that may compromise the safe performance and completion of the procedure
* Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery
* Any renal artery stenosis > 50% by visual assessment
* Any renal artery aneurysm in either renal artery
* A history of prior renal artery balloon angioplasty or stenting (for patients in Cohort A and B only, also a history of prior renal denervation at any time)

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2016
Actual
Sample size
Target
80
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
- Perth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Cardiosonic
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michael Jonas, MD
Address 0 0
Kaplan Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01835535